emocha’s $6.2 million Series A raise was recently featured in MedCity News, which tracked the company’s growth from a Johns Hopkins spinoff focused on public health and infectious disease, to now supporting medication adherence in chronic conditions like asthma and diabetes. In the last year, emocha has tripled its revenue. ”After 12 months of tremendous expansion, we are at an inflection point,” emocha CEO Sebastian Seiguer said. “Our new partners will enable us to help millions of infectious and chronic disease patients across the country take every dose of medication properly.”
